Threeway Philadelphia translocation t(9;10;22)(q34;p11.2;q11.2) as a secondary abnormality in an imatinib mesylateresistant chronic myeloid leukemia patient

By AlAchkar Walid   Wafa Abdulsamad   Ikhtiar Adnan   Liehr Thomas  

Oncology Letters, Vol. 5, Iss. 5, 2013-05 ,pp. : 1656-1658

Spandidos Publications

Access to resources Recommend Favorite

A novel cytogenetic abnormality t(7;8)(p11.2:q11.2) and a four-way Philadelphia translocation in an imatinib mesylateresistant chronic myeloid leukemia patient

By          

Oncology Letters, Vol. 5, Iss. 2, 2013-01 ,pp. : 617-620

Spandidos Publications

Access to resources Recommend Favorite

CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation

By                    

International Journal of Oncology, Vol. 47, Iss. 1, 2015-01 ,pp. : 253-261

Spandidos Publications

Access to resources Recommend Favorite

PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells

By          

International Journal of Oncology, Vol. 42, Iss. 2, 2013-01 ,pp. : 419-428

Spandidos Publications

Access to resources Recommend Favorite

Switching to second‐generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib‐treated patients with chronic myeloid leukemia with more than 10% of BCR‐ABL/ABL ratio at 3 months

By  

Cancer Medicine, Vol. 4, Iss. 7, 2015-07 ,pp. : 995-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite